Thomas J. Stout
About
Thomas J. Stout is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Thomas J. Stout has authored 50 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 16 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas J. Stout's work include Advanced Breast Cancer Therapies (11 papers), Marine Sponges and Natural Products (9 papers) and Microbial Natural Products and Biosynthesis (7 papers). Thomas J. Stout is often cited by papers focused on Advanced Breast Cancer Therapies (11 papers), Marine Sponges and Natural Products (9 papers) and Microbial Natural Products and Biosynthesis (7 papers). Thomas J. Stout collaborates with scholars based in United States, Spain and Germany. Thomas J. Stout's co-authors include Jon Clardy, Stuart L. Schreiber, David A. Evans, Stephen W. Kaldor, Todd K. Jones, Masahiko Hagihara, Neville J. Anthony, Robert M. Stroud, David J. Matthews and John A. Porco and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Chemical Society and Journal of Biological Chemistry.
In The Last Decade
Thomas J. Stout
50 papers receiving 2.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Thomas J. Stout United States | 25 | 1.1k | 906 | 292 | 281 | 271 | 50 | 2.1k | ||
| Nicola Mongelli Italy | 26 | 1.2k 1.1× | 822 0.9× | 223 0.8× | 149 0.5× | 255 0.9× | 81 | 2.1k | ||
| Arie Zask United States | 34 | 1.8k 1.7× | 1.3k 1.4× | 229 0.8× | 127 0.5× | 550 2.0× | 77 | 3.2k | ||
| Frank Totzke Germany | 30 | 1.2k 1.1× | 1.0k 1.2× | 598 2.0× | 250 0.9× | 352 1.3× | 79 | 2.6k | ||
| George S. Sheppard United States | 22 | 755 0.7× | 769 0.8× | 141 0.5× | 127 0.5× | 360 1.3× | 56 | 1.6k | ||
| Steven L. Bender United States | 16 | 1.1k 1.1× | 742 0.8× | 124 0.4× | 104 0.4× | 581 2.1× | 26 | 2.1k | ||
| Kenneth W. Bair United States | 24 | 1.4k 1.3× | 741 0.8× | 181 0.6× | 168 0.6× | 645 2.4× | 48 | 2.3k | ||
| Graham J. Atwell New Zealand | 35 | 2.4k 2.3× | 1.8k 2.0× | 237 0.8× | 148 0.5× | 676 2.5× | 111 | 3.8k | ||
| Takayoshi Kinoshita Japan | 32 | 1.5k 1.4× | 1.0k 1.1× | 179 0.6× | 126 0.4× | 461 1.7× | 142 | 3.0k | ||
| Patrick A. Marcotte United States | 33 | 1.5k 1.4× | 784 0.9× | 149 0.5× | 81 0.3× | 529 2.0× | 67 | 2.6k | ||
| Robert C. Kelly United States | 26 | 1.4k 1.3× | 1.5k 1.6× | 447 1.5× | 133 0.5× | 321 1.2× | 53 | 2.8k |
Countries citing papers authored by Thomas J. Stout
Since
Specialization
Citations
This map shows the geographic impact of Thomas J. Stout's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Stout with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Stout more than expected).
Fields of papers citing papers by Thomas J. Stout
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Thomas J. Stout. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Stout. The network helps show where Thomas J. Stout may publish in the future.
Co-authorship network of co-authors of Thomas J. Stout
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas J. Stout. A scholar is included among the top collaborators of Thomas J. Stout based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas J. Stout. Thomas J. Stout is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Juric, Dejan, Kevin Kalinsky, Nicholas C. Turner, et al.. (2024). First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.. Journal of Clinical Oncology. 42(16_suppl). 1003–1003.
2.
Chen, Jessica W., William Jacot, Javier Cortés, et al.. (2023). ER +, HER2 − advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. Molecular Oncology. 17(10). 2000–2016.
3.
Hutchinson, Katherine E., Jessica W. Chen, Heidi Savage, et al.. (2023). Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers. Genome Medicine. 15(1). 28–28.
4.
Nucíforo, Paolo, Dominik Hlauschek, Cristina Saura, et al.. (2019). Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.. Journal of Clinical Oncology. 37(15_suppl). 1050–1050.
5.
Dickler, Maura N., Cristina Saura, Donald Richards, et al.. (2018). Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer. Clinical Cancer Research. 24(18). 4380–4387.
6.
Dickler, Maura N., Cristina Saura, Donald Richards, et al.. (2016). A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).. Journal of Clinical Oncology. 34(15_suppl). 520–520.
7.
Kick, Ellen K., Richard Martin, Yinong Xie, et al.. (2014). Liver X Receptor (LXR) partial agonists: Biaryl pyrazoles and imidazoles displaying a preference for LXRβ. Bioorganic & Medicinal Chemistry Letters. 25(2). 372–377.
8.
Chmielecki, Juliann, M. Catherine Pietanza, Dana T. Aftab, et al.. (2011). EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib. Journal of Thoracic Oncology. 7(2). 434–442.
9.
Stout, Thomas J., Paul Foster, & David J. Matthews. (2004). High-Throughput Structural Biology in Drug Discovery: Protein Kinases. Current Pharmaceutical Design. 10(10). 1069–1082.
10.
Lougheed, Julie C., Ruihong Chen, Polly Mak, & Thomas J. Stout. (2004). Crystal Structures of the Phosphorylated and Unphosphorylated Kinase Domains of the Cdc42-associated Tyrosine Kinase ACK1. Journal of Biological Chemistry. 279(42). 44039–44045.
11.
Costi, Maria Paola, Marcella Rinaldi, Donatella Tondi, et al.. (1999). Phthalein Derivatives as a New Tool for Selectivity in Thymidylate Synthase Inhibition. Journal of Medicinal Chemistry. 42(12). 2112–2124.
12.
Stout, Thomas J., Carleton R. Sage, & Robert M. Stroud. (1998). The additivity of substrate fragments in enzyme–ligand binding. Structure. 6(7). 839–848.
13.
Stout, Thomas J. & Robert M. Stroud. (1996). The complex of the anti-cancer therapeutic, BW1843U89, with thymidylate synthase at 2.0 å resolution: implications for a new mode of inhibition. Structure. 4(1). 67–77.
14.
Trischman, Jacqueline A., Dianne M. Tapiolas, Paul R. Jensen, et al.. (1994). ChemInform Abstract: Salinamides A and B: Anti‐Inflammatory Depsipeptides from a Marine Streptomycete. ChemInform. 25(22).
15.
Hagihara, Masahiko, Neville J. Anthony, Thomas J. Stout, Jon Clardy, & Stuart L. Schreiber. (1992). Vinylogous polypeptides: an alternative peptide backbone. Journal of the American Chemical Society. 114(16). 6568–6570.
16.
Kimura, Yasuo, Hiromitsu Nakajima, Takashi Hamasaki, et al.. (1992). Emeniveol; A new pollen growth inhibitor from the fungus, Emericella nivea. Tetrahedron Letters. 33(46). 6987–6990.
17.
Chikashita, Hidenori, John A. Porco, Thomas J. Stout, Jon Clardy, & Stuart L. Schreiber. (1991). Synthesis of the angular anthraquinone subunit of dynemicin A. The Journal of Organic Chemistry. 56(5). 1692–1694.
18.
Evans, David A., Stephen W. Kaldor, Todd K. Jones, Jon Clardy, & Thomas J. Stout. (1990). Total synthesis of the macrolide antibiotic cytovaricin. Journal of the American Chemical Society. 112(19). 7001–7031.
19.
Zheng, Guo Qiang, et al.. (1989). Ohioensin-A: a novel benzonaphthoxanthenone from Polytrichum ohioense. Journal of the American Chemical Society. 111(14). 5500–5501.
20.
Ayer, William A., et al.. (1989). Novel sesquiterpenoids from the fairy ring fungus, Marasmiusoreades. Canadian Journal of Chemistry. 67(5). 773–778.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nicola Mongelli Breakdown of academic impact, for papers by Arie Zask Breakdown of academic impact, for papers by Frank Totzke Breakdown of academic impact, for papers by George S. Sheppard Breakdown of academic impact, for papers by Steven L. Bender Breakdown of academic impact, for papers by Kenneth W. Bair Breakdown of academic impact, for papers by Graham J. Atwell Breakdown of academic impact, for papers by Takayoshi Kinoshita Breakdown of academic impact, for papers by Patrick A. Marcotte Breakdown of academic impact, for papers by Robert C. Kelly